Stockscreener 앱 받기
4.175
3.41%
-0.155
전일 마감가:
$4.33
열려 있는:
$4.34
하루 거래량:
1.18M
Relative Volume:
0.22
시가총액:
$1.52B
수익:
$2.59M
순이익/손실:
$-137.89M
주가수익비율:
-5.1543
EPS:
-0.81
순현금흐름:
$-69.76M
1주 성능:
+3.01%
1개월 성능:
+8.92%
6개월 성능:
+98.22%
1년 성능:
+240.03%
1일 변동 폭
$4.11
$4.36
1주일 범위
$3.88
$4.72
52주 변동 폭
$1.15
$6.75
Atai Beckley N V Stock (ATAI) Company Profile
명칭
Atai Beckley N V
전화
49 89 2153 9035
주소
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
ATAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATAI
Atai Beckley N V
|
4.185 | 1.57B | 2.59M | -137.89M | -69.76M | -0.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.92 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
786.09 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.51 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.39 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.44 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atai Beckley N V Stock (ATAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-07-29 | 개시 | Oppenheimer | Outperform |
| 2024-11-18 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-03 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
| 2021-11-11 | 개시 | ROTH Capital | Buy |
| 2021-10-18 | 개시 | H.C. Wainwright | Buy |
| 2021-09-01 | 개시 | Jefferies | Buy |
| 2021-07-13 | 개시 | Berenberg | Buy |
| 2021-07-13 | 개시 | Canaccord Genuity | Buy |
| 2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-13 | 개시 | Credit Suisse | Outperform |
| 2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Atai Beckley N V 주식(ATAI)의 최신 뉴스
JonesTrading Initiates Coverage on ATAI Life Sciences With Buy Rating, $16 Price Target - marketscreener.com
Jones Trading initiates Buy rating on atai Life Sciences stock with $16 target - Investing.com
AtaiBeckley joins the Nasdaq Biotechnology Index - Proactive financial news
Atai Beckley Added to Nasdaq Biotechnology Index - marketscreener.com
Atai Beckley N.V. Added to NASDAQ Biotechnology Index, Marking a Significant Milestone for the Company - Quiver Quantitative
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
MarketBeat's Top 5 Rated Small-Cap Stocks - Finviz
Atai Beckley N.V.(NasdaqGM: ATAI) added to NASDAQ Biotechnology Index - marketscreener.com
Psychedelics stocks could benefit from marijuana rescheduling: Jefferies - MSN
How Does Atai (ATAI)’s New EMP-01 Patent Shape Its Psychedelic Therapy Moat? - simplywall.st
Atai Life Sciences N.V. (ATAI) Secures Patent for Social Anxiety Disorder Formulation - Insider Monkey
CapEx per share of Atai Beckley N.V – LSX:A3CSB4 - TradingView — Track All Markets
New EMP-01 Patent Win Could Be A Game Changer For Atai Beckley (ATAI) - simplywall.st
ATAI Beckley Secures US Patent for EMP-01 to Treat Social Anxiety Disorder; Shares Up Pre-Bell - marketscreener.com
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio - The Manila Times
AtaiBeckley (NASDAQ: ATAI) gains EMP-01 patent, eyes Phase 2a data in 2026 - Stock Titan
Atai Beckley files prospectus supplement for registered shares after Beckley Psytech acquisition - Investing.com Australia
Atai Beckley files prospectus supplement for registered shares after Beckley Psytech acquisition By Investing.com - Investing.com South Africa
ATAI Life Sciences Files Prospectus for Share Registration - TipRanks
Atai Beckley N.V. Files Prospectus Supplement for Common Shares - TradingView — Track All Markets
Atai Life Sciences (ATAI): Assessing an 8.8x Price-to-Book Valuation After a Volatile Share Price Run - Yahoo Finance
Atai Beckley (ATAI) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
ATAIAtai Beckley N.V Short Interest - Finviz
ATAI Life Sciences Files Prospectus for Share Resale - MSN
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates - ADVFN
Form 8-KCurrent report - ADVFN
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - ADVFN
[Form 4] Atai Beckley N.V. Insider Trading Activity - Stock Titan
H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion - MSN
Atai Beckley N.V. (ATAI) latest stock news and headlines - Yahoo Finance UK
AtaiBeckley advances BPL-003 toward Phase 3 After Strong Phase 2 Data topline data i - Proactive financial news
9 Oversold Biotech Stocks to Invest In - Insider Monkey
Atai Beckley NV (NASDAQ:ATAI)Shares, Dividends & News - intelligentinvestor.com.au
Enhanced (ATAI) overhauls leadership, appoints new CEO, executive chairman and CFO - Stock Titan
Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato - MSN
Atai Beckley N.V (ATAI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
H.C. Wainwright reiterates Buy rating on atai Life Sciences stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on atai Life Sciences stock - Investing.com India
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London - The Manila Times
AtaiBeckley (NASDAQ: ATAI) London fireside chat at 11:30 GMT; replay for 90 days - Stock Titan
AtaiBeckley advances clinical pipeline, strengthens balance sheet in Q3 - Proactive financial news
Atai Beckley Q3 Loss Widens, Revenue Rises; Shares Down Pre-Bell - MarketScreener
[8-K] ATAI Life Sciences N.V. Reports Material Event | ATAI SEC FilingForm 8-K - Stock Titan
Atai Beckley N.V. Announces Breakthrough Therapy Designation for BPL-003 and Positive Phase 2 Results for Treatment-Resistant Depression - Quiver Quantitative
Earnings Flash (ATAI) Atai Beckley N.V. Reports Q3 Revenue $749,000 - MarketScreener
Earnings Flash (ATAI) Atai Beckley Posts Q3 Net Loss $0.28 a Share, vs. FactSet Est of $0.11 Loss - MarketScreener
AtaiBeckley (NASDAQ: ATAI) closes approx. $150M offering, funding into 2029 - Stock Titan
Atai Beckley N V (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.31%
1.24%
자본화:
|
볼륨(24시간):